Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 393

1.

Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.

Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A.

Lung Cancer. 2019 Jul;133:136-143. doi: 10.1016/j.lungcan.2019.05.020. Epub 2019 May 19.

PMID:
31200820
2.

Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.

Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S.

Mol Carcinog. 2019 Apr 21. doi: 10.1002/mc.23026. [Epub ahead of print]

PMID:
31006917
3.

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.

Wang C, Kulkarni P, Salgia R.

Mol Ther Oncolytics. 2019 Mar 19;13:1-6. doi: 10.1016/j.omto.2019.02.001. eCollection 2019 Jun 28. Review.

4.

Early mortality of stage IV non-small cell lung cancer in the United States.

Amini A, Verma V, Glaser SM, Shinde A, Sampath S, Stokes WA, Rusthoven CG, Massarelli E, Salgia R, Gaspar LE, Liu AK.

Acta Oncol. 2019 Apr 8:1-7. doi: 10.1080/0284186X.2019.1599138. [Epub ahead of print]

PMID:
30958075
5.

Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2019 Apr;18(4):868. doi: 10.1158/1535-7163.MCT-18-1183. No abstract available.

PMID:
30936412
6.

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies.

Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R.

Clin Transl Med. 2019 Mar 18;8(1):9. doi: 10.1186/s40169-019-0225-x. Review.

7.

Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.

Lin X, Kulkarni P, Bocci F, Schafer NP, Roy S, Tsai MY, He Y, Chen Y, Rajagopalan K, Mooney SM, Zeng Y, Weninger K, Grishaev A, Onuchic JN, Levine H, Wolynes PG, Salgia R, Rangarajan G, Uversky V, Orban J, Jolly MK.

Biomolecules. 2019 Feb 22;9(2). pii: E77. doi: 10.3390/biom9020077.

8.

RLIP: An existential requirement for breast carcinogenesis.

Singhal SS, Salgia R, Singhal S, Horne D, Awasthi S.

Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):281-288. doi: 10.1016/j.bbcan.2019.02.001. Epub 2019 Feb 13. Review.

PMID:
30771458
9.

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R.

Am J Clin Oncol. 2019 Apr;42(4):337-344. doi: 10.1097/COC.0000000000000508.

PMID:
30741758
10.

RLIP inhibition suppresses breast-to-lung metastasis.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Cancer Lett. 2019 Apr 10;447:24-32. doi: 10.1016/j.canlet.2019.01.023. Epub 2019 Jan 23.

PMID:
30684594
11.

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND.

Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.

PMID:
30660729
12.

The DNA Walk and its Demonstration of Deterministic Chaos- Relevance to Genomic Alterations in Lung Cancer.

Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R.

Bioinformatics. 2019 Jan 7. doi: 10.1093/bioinformatics/bty1021. [Epub ahead of print]

PMID:
30615123
13.

Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2018 Dec 1;24(23):6099. doi: 10.1158/1078-0432.CCR-18-3194. No abstract available.

PMID:
30510088
14.

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.

Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R.

Cancer Biol Ther. 2018 Oct 12:1-10. doi: 10.1080/15384047.2018.1472193. [Epub ahead of print]

15.

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.

Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R.

Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9. Review.

16.

Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.

Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A.

Semin Oncol. 2018 Aug;45(4):210-219. doi: 10.1053/j.seminoncol.2018.06.002. Epub 2018 Jul 1. Review.

PMID:
30286944
17.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
18.

2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS.

J Proteomics. 2019 Feb 10;192:233-245. doi: 10.1016/j.jprot.2018.09.005. Epub 2018 Sep 21.

PMID:
30248461
19.

Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.

Singhal J, Singhal P, Horne D, Salgia R, Awasthi S, Singhal SS.

Cancer Lett. 2018 Dec 1;438:144-153. doi: 10.1016/j.canlet.2018.09.015. Epub 2018 Sep 15.

PMID:
30223070
20.

2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Mol Carcinog. 2018 Dec;57(12):1751-1762. doi: 10.1002/mc.22894. Epub 2018 Sep 19.

PMID:
30136444
21.

Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.

Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R.

J Oncol Pract. 2018 Sep;14(9):569-571. doi: 10.1200/JOP.18.00127. Epub 2018 Jul 25. No abstract available.

PMID:
30044685
22.

Heuristic value-based framework for lung cancer decision-making.

Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R.

Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643. eCollection 2018 Jul 6.

23.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

PMID:
29948021
24.

Graft-versus-host disease of the central nervous system after liver transplantation: A rare complication.

Pahari H, Nagai S, Skorupski S, Salgia R.

Am J Transplant. 2018 Oct;18(10):2591-2594. doi: 10.1111/ajt.14981. Epub 2018 Jul 20.

PMID:
29935052
25.

Chances of Renal Recovery or Liver Transplantation After Hospitalization for Alcoholic Liver Disease Requiring Dialysis.

Lenhart A, Hussain S, Salgia R.

Dig Dis Sci. 2018 Oct;63(10):2800-2809. doi: 10.1007/s10620-018-5170-9. Epub 2018 Jun 22.

PMID:
29934721
26.

Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P.

J Clin Med. 2018 Jun 17;7(6). pii: E156. doi: 10.3390/jcm7060156. Review.

27.

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M.

Oncotarget. 2018 May 25;9(40):26226-26242. doi: 10.18632/oncotarget.25360. eCollection 2018 May 25. Review.

28.

Managing Patients With Relapsed Small-Cell Lung Cancer.

Gong J, Salgia R.

J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204.

29.

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.

Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R.

Oncotarget. 2018 Apr 13;9(28):19793-19806. doi: 10.18632/oncotarget.24857. eCollection 2018 Apr 13.

30.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
31.

2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.

Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS.

Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.

32.

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R.

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032. No abstract available.

PMID:
29685646
33.

Value-based genomics.

Gong J, Pan K, Fakih M, Pal S, Salgia R.

Oncotarget. 2018 Jan 30;9(21):15792-15815. doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20. Review.

34.

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.

Mambetsariev I, Vora L, Yu KW, Salgia R.

BMC Cancer. 2018 Mar 21;18(1):314. doi: 10.1186/s12885-018-4222-z.

35.

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M.

Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.

36.

Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).

Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):177-185. doi: 10.1016/j.ijrobp.2018.01.046. Epub 2018 Jan 31.

37.

The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.

Salgia R, Kulkarni P.

Trends Cancer. 2018 Feb;4(2):110-118. doi: 10.1016/j.trecan.2018.01.001. Epub 2018 Feb 3. Review.

38.

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Amanam I, Gupta R, Mambetsariev I, Salgia R.

Future Oncol. 2018 Aug;14(19):1897-1908. doi: 10.2217/fon-2017-0545. Epub 2018 Feb 16.

PMID:
29451020
39.

EphB4: A promising target for upper aerodigestive malignancies.

Salgia R, Kulkarni P, Gill PS.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137. doi: 10.1016/j.bbcan.2018.01.003. Epub 2018 Jan 31. Review.

40.

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R.

J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z. Review.

41.

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.

42.

Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States.

Jinjuvadia R, Salami A, Lenhart A, Jinjuvadia K, Liangpunsakul S, Salgia R.

Am J Med Sci. 2017 Oct;354(4):362-369. doi: 10.1016/j.amjms.2017.05.016. Epub 2017 Jun 1.

43.

State-of-the-art considerations in small cell lung cancer brain metastases.

Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R.

Oncotarget. 2017 Jul 18;8(41):71223-71233. doi: 10.18632/oncotarget.19333. eCollection 2017 Sep 19. Review.

44.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.

Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M.

Oncotarget. 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15.

45.

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J.

Oncotarget. 2017 Sep 22;8(37):62817. doi: 10.18632/oncotarget.20632. eCollection 2017 Sep 22.

46.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.

47.

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.

Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R.

Sci Rep. 2017 Aug 23;7(1):9192. doi: 10.1038/s41598-017-09078-4.

48.

Outcome of liver transplantation in patients with prior bariatric surgery.

Safwan M, Collins KM, Abouljoud MS, Salgia R.

Liver Transpl. 2017 Nov;23(11):1415-1421. doi: 10.1002/lt.24832.

49.

Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention.

Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V.

Eur J Oncol Nurs. 2017 Aug;29:125-134. doi: 10.1016/j.ejon.2017.06.003. Epub 2017 Jun 19.

50.

Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.

Wood K, Byron E, Janisch L, Salgia R, Sharma MR.

Am J Clin Oncol. 2018 Oct;41(10):963-966. doi: 10.1097/COC.0000000000000400.

PMID:
28654574

Supplemental Content

Loading ...
Support Center